Literature DB >> 9817532

Etiology and pathogenesis of multiple sclerosis.

T L Sørensen1, R M Ransohoff.   

Abstract

The cause of multiple sclerosis (MS) remains unknown despite decades of intense research. The major research disciplines that have been brought to bear on this question include genetics, epidemiology, neuropathology, immunology, and virology. Recent advances in the understanding of the inflammatory characteristics of the MS lesion may herald the development of specific and effective treatments. The goal of this research is to improve our management of a disease that remains the major cause of neurologic disability among young adults in North America and Europe.

Entities:  

Mesh:

Year:  1998        PMID: 9817532     DOI: 10.1055/s-2008-1040879

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  10 in total

Review 1.  Immunologic therapy for relapsing-remitting multiple sclerosis.

Authors:  H J MacLean; M S Freedman
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

2.  CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

Authors:  C Trebst; T L Sørensen; P Kivisäkk; M K Cathcart; J Hesselgesser; R Horuk; F Sellebjerg; H Lassmann; R M Ransohoff
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  CXC and CC chemokine receptors on coronary and brain endothelia.

Authors:  O Berger; X Gan; C Gujuluva; A R Burns; G Sulur; M Stins; D Way; M Witte; M Weinand; J Said; K S Kim; D Taub; M C Graves; M Fiala
Journal:  Mol Med       Date:  1999-12       Impact factor: 6.354

4.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients.

Authors:  T L Sørensen; M Tani; J Jensen; V Pierce; C Lucchinetti; V A Folcik; S Qin; J Rottman; F Sellebjerg; R M Strieter; J L Frederiksen; R M Ransohoff
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

5.  Overexpression of glia maturation factor reinstates susceptibility to myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in glia maturation factor deficient mice.

Authors:  Smita Zaheer; Yanghong Wu; Shailendra K Sahu; Asgar Zaheer
Journal:  Neurobiol Dis       Date:  2010-08-07       Impact factor: 5.996

6.  Optic neuritis: chemokine receptor CXCR3 and its ligands.

Authors:  T L Sørensen; H Roed; F Sellebjerg
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

7.  Microglial process convergence on axonal segments in health and disease.

Authors:  Savannah D Benusa; Audrey D Lafrenaye
Journal:  Neuroimmunol Neuroinflamm       Date:  2020-03-21

8.  Matrix metalloproteinases, synaptic injury, and multiple sclerosis.

Authors:  Arek Szklarczyk; Katherine Conant
Journal:  Front Psychiatry       Date:  2010-10-05       Impact factor: 4.157

9.  A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation.

Authors:  Michelle L Scalley-Kim; Bruce W Hess; Ryan L Kelly; Anne-Rachel F Krostag; Kurt H Lustig; John S Marken; Pamela J Ovendale; Aaron R Posey; Pamela J Smolak; Janelle D L Taylor; C L Wood; David L Bienvenue; Peter Probst; Ruth A Salmon; Daniel S Allison; Teresa M Foy; Carol J Raport
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

10.  Cloning, expression and characterization of ferret CXCL10.

Authors:  Ali Danesh; Charit Seneviratne; Cheryl M Cameron; David Banner; Mark E Devries; Alyson A Kelvin; Luoling Xu; Longsi Ran; Steven E Bosinger; Thomas Rowe; Marcus Czub; Colleen B Jonsson; Mark J Cameron; David J Kelvin
Journal:  Mol Immunol       Date:  2007-11-19       Impact factor: 4.407

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.